Study Finds Ruxolitinib Effective, Safe for Children With AD

There were no significant safety signals in the younger pediatric population, and 'no treatment-emergent adverse events suggestive of systemic JAK inhibition,' Dr Lawrence Eichenfield said.

Related Keywords

San Diego , California , United States , Norway , Berlin , Germany , Lawrencef Eichenfield , Thrasyvoulos Tzellos , European Academy Of Dermatology , University Of California , Nordland Hospital , European Academy , Global Assessment , Numerical Rating Scale , Nordland Hospital Trust , Dermatitis , Children , Child , Childhood , Ediatrics , Kids , Pain Management , Dermatology Pediatric , Atopic Dermatitis , Adolescent Medicine , Plasma , Pruritus , Pruritis , Pitch , Patient Safety , Rheumatoid Arthritis , A , Thrombus , Leukemia , Anti Inflammatory Agents , Arthritis , Oint Inflammation , Blood , , Cancer , Alignant Neoplasia , Arcinoma , Drug Treatment Safety , Eczema , Europe , European , Hea ,